Hesco announced that it has obtained the "acceptance notice" of the application for HSK36273 clinical trials for innovative drugs. HSK36273 for injection is an intravenous anticoagulant EP7041 introduced by the company. Hisco has its exclusive license in mainland China for clinical use in hemodialysis and systemic anticoagulation in patients during surgery.
The chairman of the company is Wang Junmin. Wang Junmin, male, born in 1968, Chinese nationality, permanent residence in Singapore, graduated from Cheung Kong Business School, master's degree. Mr. Wang Junmin was the sales manager of the pharmaceutical factory of West China Medical University, the chairman and general manager of Haiske Pharmaceutical Group Co., Ltd from 2007 to March 2019, and the chairman of the company since March 2019.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If you have any questions, please contact us.